Table of Contents

HK J Paediatr (New Series)
Vol 18. No. 2, 2013

HK J Paediatr (New Series) 2013;18:96-104

Clinical Guideline

Clinical Guidelines on Management of Atopic Dermatitis in Children

TNH Leung, CM Chow, MPY Chow, DCK Luk, KM Ho, KL Hon, vK Sugunan


Disclaimer

These guidelines have been developed by the Hong Kong College of Paediatricians and the authors, according to the state of medical knowledge at the time of compilation. These guidelines are for general guidance only and are designed to provide information to assist decision-making. Paediatricians should use their up-to-date medical knowledge, clinical data of the patients and their own clinical judgement in applying the recommendations in this document to the management of individual patients.


Introduction

Atopic dermatitis or atopic eczema is one of the commonest childhood skin conditions affecting 5.6% of young children;1 and 3.8% school children and adolescents in Hong

Kong.2,3 Currently, there are at least four evidence-based international guidelines on management of atopic dermatitis.4-7 Among these, "Atopic Eczema in Children" published by National Institute for Health and Clinical Excellence (NICE) in December 2007 is the only one specific for children from birth to 12 years.4 The NICE guidelines include comprehensive recommendations on diagnosis, assessment and management with reference to currently available evidences. The guidelines will be regularly reviewed and updated. A quick reference guide summarising the recommendations is available on the internet http://www.nice.org.uk/nicemedia/live/11901/38566/38566.pdf. The guideline development and review panel members appointed by the Hong Kong College Paediatricians agreed to refer to this set of guidelines for clinical practice recommendations. This paper highlights the key points in the NICE guidelines with additional recommendations relevant for local practice.

Diagnosis

  • Atopic dermatitis is described as chronic relapsing pruritic dermatitis mostly in individuals with atopic background. The NICE guidelines describe diagnostic features specifically for children having an itchy skin condition plus ≥ 3 of the following:
    • visual flexural dermatitis involving skin creases (or visible dermatitis on cheeks and or extensor areas in children ≤ 18 months)
    • personal history of flexural dermatitis (for typical age specific pattern as above)
    • personal history of dry skin in the last 12 months
    • personal history of asthma or allergic rhinitis (or history of atopic disease in a first degree relative of children <4 years )
    • onset of signs and symptoms under the age of 2 years
  • Alternative diagnoses have to be considered in patients not responding to standard treatment.

Assessment of Severity

  • Scoring of severity is not required for daily clinical practice. Documentation with description of extent and nature of lesions, skin dryness and intensity of itchiness would guide management in stepwise approach (Table 1).
  • Assessment of impact on family activities and quality of life are relevant to deliver holistic care for the family.
Table 1 Stepwise treatment of atopic dermatitis in children



STEP UP
according
to
severity
Level of severity Signs and symptoms Treatment
Severe Widespread areas of dry skin
Incessant itching
Redness +/- excoriation
Extensive skin thickening
Bleeding, oozing, cracking and alteration of pigmentation
Potent to very potent TCS
Systemic immunosuppressants (e.g. azathioprine) or phototherapy for older children who fail to respond after optimisation of topical treatments and skin care
Moderate Areas of dry skin
Frequent itching
Redness +/- excoriation or localised skin thickening
Moderate to potent TCS
TCI as second line treatment & antibiotics for clinical secondary infections
Mild Areas of dry skin
Infrequent itching
Small areas of redness
Mild to moderate potent TCS
TCI as second line treatment
Dry skin only No active lesions Basic treatment:
Skin hydration, emollients, avoidance of irritants
Identification & addressing specific trigger factors
TCS: topical corticosteroids; TCI: topical calcinerin inhibitors

Identification of Triggers

  • Identification of possible triggers is an essential part of the clinical assessment with reference to age, pattern of exacerbation and social factors. Common triggers include irritants (e.g. soaps and detergents), infections, seasonal flares and allergens (contact, foods or inhaled).
  • General advice on clothing and avoidance of skin irritants such as soap, detergent and smoke are recommended.
  • Food allergy and infections will be discussed in separate sections below.

Management Goals7

  • The management goals aim at prevention of skin damage and chronic eczema through:
    • achieving a state of no or minor symptoms with daily life not disturbed and not much medication needed or
    • even if slight or mild symptoms last, exacerbations are rarely acute, intense or protracted

Stepwise Management Approach

  • Management according to disease severity is generally recommended by most guidelines.4-6 Table 1 summarises management options according to severity.

Treatment

1. Emollients or Moisturisers

  • Skin dryness and reduced ceramides are common in eczema. Emollients or moisturisers are products to maintain skin hydration and prevent skin dryness through reducing transepidermal water loss in eczema patients with skin barrier dysfunction.8
  • All patients require an essential package of emollient therapy including a topical emollient and a wash product, disregarding the severity and the activity of the disease.
  • Preparations ranged from aqueous lotions, oil-in-water or water-in-oil creams to predominant oil based ointment. Children's needs and preferences should also be considered in choosing emollients because the correct emollient is the one that the child will use. The choice should depend on individual skin status, seasonal and climatic conditions, and the time of day.5
  • Emollients should be used in large quantities and frequently - at least three times a day including after bathing.4 Hydration of skin can be improved by "Soak and Seal": Bathing daily in lukewarm water using emollients as soap substitute for 5-10 minutes, pat dry with towel and avoid rubbing which can induce itchiness, followed by immediate application of emollients.8
  • Side effects are uncommon, but contact dermatitis, occlusion folliculitis and irritant adverse skin reactions such as stinging were reported. Recently, there are concerns on sodium lauryl sulphate (SLS) containing emollients (e.g. some preparations of aqueous cream and emulsifying ointment). SLS is an irritating chemical and clinical studies showed that continuous application for a few weeks were associated with decrease in stratum corneum thickness and increase in transepidermal water loss.8 These emollients are more appropriately used as a soap substitute rather than left-on moisturisers.8
  • Newer emollients containing ceramides and pseudoceramides are developed targeting to the pathophysiology of atopic dermatitis. However, further clinical studies are required to assess the efficacy and acceptability of these products.9

2. Topical Corticosteroids (TCS)

  • TCS has anti-inflammatory, immunosuppressive, anti-proliferative effects, inhibit collagen synthesis and local vasoconstriction in atopic eczema.
  • It should be noted that different types and potency of TCS could be used for different severity of lesions on specific locations of a patient.
  • Formulations
    • Ointments have fewer ingredients than creams and generally no preservatives, hence less chance of allergy
    • Creams and lotions are less occlusive and safer as a base for TCS. Lotions can spread easily across skin surface, more suitable for hairy areas and large body surface area
  • Potency
    • Potency of TCS is classified according to vasoconstrictor assay which correlates with clinical efficacy in only 62% of topical steroid preparations. TCS of various classes of potency and formulations available in Hong Kong are listed in Table 2.
    • Mild and moderate potent TCS are generally safe while potent and very potent TCS may cause adrenal suppression.
    • Potency of TCS should be tailored to the severity of lesions which may vary according to body site. Potent and very potent TCS should be used only with specialist dermatological advice.
    • The potency of same type of steroid in different bases is not exactly equivalent. Usually the ointment base is more potent than cream base. e.g. Elomet ointment is significantly more potent than cream.
  • Dosage and Frequency
    • Finger tip unit (FTU) is a validated method for applying TCS in safe quantities.10 One FTU is a squeeze of cream or ointment along the index finger from the tip to the first finger joint and weighs approximately half a gram; enough to cover a surface area of two adult palms including fingers.
    • Apply once or at most twice per day. Do not apply emollient immediately after topical steroid. It is advisable to wait for at least 30 minutes between application of emollients and TCS to avoid dilution and spread of TCS to unaffected skin.11
  • Treatment of Flares
    • Use only on eczema that has been active in the past 48 hours.
    • Start treatment as soon as signs and symptoms appear and continue for approximately 48 hours after symptoms subside.
    • Use the appropriate potency of steroids according to severity of lesions. Use mild TCS for areas prone to adverse effect including face, neck, axilla and groin.
    • In case of severe flares, more potent steroids can be used but duration of use should be limited (use newer topical steroids e.g. Mometasone furoate, Methylprednisolone aceponate, Fluticasone proprionate; avoid old halogenated steroids e.g. Fluocinolone acetonide):
      • Face and neck: moderate or potent TCS for 3-5 days
      • Axillae and groin: moderate or potent TCS no more than 1-2 weeks
      • Trunk and limbs: potent TCS for no more than 2 weeks
    • Consider infections and other causes if no clinical response in 7-14 days using a mild or moderate potent TCS
    • In children with two or three flares per month, apply TCS for two consecutive days per week to prevent flares.5
  • Side effects and precautions
    • Cutaneous complications include striae, atrophy, telangiectasia and perioral dermatitis
    • Systemic complications such as Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) axis suppression, growth retardation, osteoporosis and hypertension are rare.6,12
    • Risk factors for complications are associated with
      • Potent and very potent TCS
      • Young child who has potential for increased absorption caused by a higher ratio of skin surface area to body mass
      • Occlusion
      • Application over extensive areas
      • Skin barrier function compromised
    • Tachyphylaxis may occur in some patients and can be managed by changing to another TCS of same potency.4 It can be prevented by intermittent use such as week on week off or 3 days on 4 days off.13
Table 2 Potency of common topical corticosteroids available in Hong Kong
Potency Generic name (in alphabetical order within the potency group) Common trade names Strength Formulation
Mild Hydrocortisone Hydrocortisone 0.5%, 1% C/O/L
Moderate Clobestasone butyrate Eumovate 0.05% C
Fluocinolone acetonide Synalar 0.005% & 0.0125% C/O
Potent Betamethasone dipropionate Diprosone 0.05% C/O
Betamethasone valerate Betnovate 0.1% C/O/L
Fluocinolone acetonide Synalar 0.025% C/O/gel
Fluticasone proprionate Cutivate 0.05% C
Methylprednisolone aceponate Advantan 0.1% C/O
Mometasone furoate Elomet 0.1% C/O/L
Triamcinolone Aristo 0.1% C/O
Very potent Betamethasone dipropionate in propylene glycol Diprocel 0.05% C/O
Clobetasol propionate Dermovate 0.05% C/O/L
Diflucortolone valerate Nerisone 0.1% Fatty ointment
O=Ointment, C=Cream, L=liquid which includes lotion# and those label as "scalp application"
References: British National Formulary for children 2011 (BNF) and MIMS(HK) 130th 2012 edition
#Lotion conventionally refers to liquid formulation with aqueous base, but may sometimes be loosely used in formulation with alcohol base. Doctors should refer to product insert for details as alcohol-based formulation cause irritation to the inflam

3. Wet-wrap with Diluted TCS

  • Indicated for treatment of resistant severe eczema and erythrodermic eczema. It should not be used as first line therapy for mild to moderate atopic eczema.
  • Contraindicated in heavily infected eczema, impetigo and eczema herpeticum. Pubertal age is a relative contraindication for risk of striae development.
  • It should only be started by healthcare professional trained in their use. Parents have to be trained under supervision.
  • It can be used for isolated body parts or whole body for widespread lesions.
  • Duration of use with diluted TCS: maximum 1-2 weeks, can be continued with emollients alone for longer duration.
    Techniques of wet-wrap14
    • Materials
      • Cotton tubular bandages (e.g. Tubifast) of appropriate sizes cut to fit the body part for wet-wrap (Clothing, gloves and socks made with cotton dressings for wet-wrap are also commercially available).
      • Smaller bandages as ties
    • Choice of topical drugs:
      • Emollients only
      • Emollients in combination with antiseptics
      • TCS : Most commonly using 10% dilutions of potent TCS. Dilute TCS 1:10 with emollients of similar formulations (i.e. TCS creams with aqueous emollient, TCS ointment with oil based emollients). There are studies demonstrating that using greater dilutions of TCS (e.g. 1:20) reduces the risk of systemic bioactivity, while maintaining a good efficacy
    • Steps
      • After bath/shower with emollients, pat to remove excess water on body
      • Apply the topical preparation (emollients or diluted TCS) to the damp skin immediately to enhance water absorption and seal in moisture
      • Put bandages in lukewarm water of body temperature, squeeze water out of the bandages and then apply; followed by another layer of dry tubular bandage. Put ties to fix bandages of different body parts.
      • Perform in a warm room to avoid patients becoming chilled
      • Rewet bandage every 2 hours with water using a spray bottle (optional)
      • Keep for 8-12 hours overnight

4. Topical Calcineurin Inhibitors (TCI)15

  • There are 3 preparations of topical calcineurin inhibitors available:
    TCI Suggested age indication
    1% pimecrolimus cream ≥ 2 years old according to FDA (USA) and BNF (UK), approved for ≥ 3 months old in some regions like Hong Kong, Australia and New Zealand.
    0.03% tacrolimus ointment ≥ 2 years old
    0.1% tarcolimus ointment ≥ 16 years old
  • TCI have been shown to reduce the extent, severity and symptoms of atopic dermatitis in children and adults, particularly beneficial when treating delicate sites such as the face, neck and intertriginous regions where skin atrophy may be a concern.
  • The most commonly reported adverse reactions include transient burning and erythema which often subside upon continuation of use for a few days.16 During the course of treatment, sun exposure should be minimised.
  • The Pediatric Advisory Committee of the USA FDA implemented a 'black box' warning for TCIs due to the lack of long-term safety data and the potential risk of the development of malignancies in 2006.17 It is also generally agreed that treatment with TCIs is a second-line treatment for short or medium term use. In the NICE guidelines, it is recommended that TCIs should be initiated only by physicians with a special interest and experience in dermatology, and only after careful discussion with the patient about the potential risks and benefits of all appropriate second-line treatment options.4

5. Oral antihistamines

  • There are only a few randomised controlled trials in evaluating sedating or non-sedating antihistamines for atopic eczema and there is no clear evidence to suggest that these are effective in treating atopic eczema.
  • Clinically it is still worthwhile to give a trial of 7-14 days of sedating antihistamines for children older than 6 months in acute flares where there is significant sleep disturbance.
  • Alternatively, age appropriate non-sedating antihistamines for 1 month trial may also be considered in cases where itch is a prominent symptom.

6. Systemic Anti-inflammatory Therapy18

  • Systemic corticosteroids, cyclosporin A and azathioprine have been tried in the treatment of severe, recalcitrant atopic eczema in children. Recommendations are based on small randomised controlled trials, uncontrolled trials and case reports. Limited evidences are available for other systemic therapy including Mycophenolate mofetil, Methotrexate, interferon gamma, infliximub and montelukast.
    • Systemic corticosteroids
      • These are used in severe acute exacerbations and are rapidly effective. Two randomised controlled trials done in children using beclomethasone diproprionate and flunisolide while study on prednisolone, the commonest glucocorticosteroid used in clinical practice, is lacking. Treatment should be limited to short duration due to the many long-term side-effects.
    • Cyclosporin A
      • The recommended dosage is 3-5 mg/kg/day and the efficacy is dose related. Clinical effects can be seen after 6 to 8 weeks of treatment.
      • The narrow therapeutic index requires a close follow-up. Side effects include nephrotoxicity, hyperlipidaemia, hypertension, hypertrichosis, gingival hyperplasia and malignancies. It is recommended to limit the treatment to one year due to its side effects.
      • Relapse after discontinuation is reported in a study by Harper and colleagues showing 86% of patients had an increase in disease activity to more than 75% of the pre-treatment severity within 9 months of cessation of treatment.19
    • Azathioprine
      • Azathioprine has a slower onset of action in terms of a few weeks to a few months; and is not always well tolerated.
      • Patient with a low blood thiopurine-methyltransferase (TPMT) activity are more susceptible to myelotoxicity and hepatotoxicity. Ideally, blood TPMT level should be measured prior to starting azathioprine and dosage should be adjusted accordingly, but the test is not readily available in Hong Kong. Dosage ranged from 1-3 mg/kg/day.

7. Phototherapy 20

  • Phototherapy using ultraviolet light (UVA or UVB) with or without psoralen has been used in atopic eczema since 1940s. In recent years, narrow band UVB and long wave UVA (UVA1) are used most often in atopic eczema.
  • In general, phototherapy is useful in older children with chronic stages of atopic dermatitis. Erythema and skin dryness are common and exact risk associated with skin cancer is not known. With the availability of other safer treatments, phototherapy should only be used in children when other therapies have failed, after careful consideration and with specialist supervision.

Management of Infections

  • Staphylococcus aureus colonization is found in almost all patients with eczema. It can act as superantigen and contribute to the severity of atopic eczema. Streptococcus pyogenes can also cause skin infection. Eczema herpeticum is a potentially life threatening infection of eczematous skin with herpes simplex virus. An acute flare up may actually be secondary to the skin infection. In bacterial infection, the skin condition deteriorates more acutely, appears erythematous, weeping with crusts and pustules. Herpes infection should be considered in patients with blister, punched out painful erosions or failure to respond to antibiotics and TCS. Skin swabs for bacterial, viral and fungal cultures may be useful in selected cases.
  • Topical antibiotic or antiseptic cream can be used in localised skin infection. Appropriate oral antibiotics that are active against staphylococcus and streptococcus should be given to patients with more widespread or severe infection. The usual duration of systemic treatment is 1 to 2 weeks. Systemic antiviral therapy, together with other supportive therapies is needed in eczema herpeticum.
  • Bathing with diluted bleach (~0.005% sodium hypochlorite) twice weekly and topical use of nasal mupirocin twice daily for 5 consecutive days each month, for a total period of 3 months has been shown to improve eczema by reducing staphylococcal colonisation.21

Food Allergy and Diet Intervention

Food allergy has been reported in 33-63% of children with atopic eczema.22 The lately published NICE guidelines on "Food allergy in children and young people" in 2011 have detailed recommendations on evaluation and management concerning food allergy.23 The European Academy of Allergology and Clinical Immunology (EAACI) recently published one position paper with recommendations on evaluation of eczematous reactions to food in atopic eczema.22 The following are some important points to note:

  • A good allergy-focused clinical history is essential and further evaluation is only indicated in selected patients with a positive history or persistent moderate to severe eczema not responding to standard treatment.
  • Common food allergens attributed to exacerbations of eczema include milk, eggs, peanuts, soy and wheat. Typical immediate IgE-mediated reactions include acute urticaria, angioedema and anaphylaxis. Flares of eczematous lesions occurring hours to days are more likely non-IgE mediated.
  • Tests of allergen hypersensitivity including skin prick test and specific IgE antibody are used for assessing IgE-mediated sensitisation. Age specific cut-off levels for diagnostic decision of these tests are available for only a limited number of food allergens and results have to be interpreted with consideration of the clinical context.24 The role of serum specific IgG to food allergens is unclear and should not be used for diagnosis of food allergy.
  • In patients with a clear history and non-IgE mediated allergy is suspected, elimination of the suspected allergen can be tried for 4-6 weeks. If patients responded to elimination, oral food challenge is required to confirm that relation of food allergy and eczematous reactions.
  • For infants suspected to have cow's milk protein allergy (CMPA), a trial of extensively hydrolysed or amino-acid formula for 6-8 weeks is recommended. Partially hyrolysed formula may have a role in prevention but not for treatment of CMPA. Soy-based formula contains phytoestrogens and is not recommended for children <6-10 months in UK and some European countries. Cross-reactivity with soy protein has been reported in about 30-50% of cases of CMPA.25 Goat's milk is not recommended as it is nutritionally inadequate and shares 95% of cross-reacting allergens with cow's milk.
  • Specific food-free diet should only be considered when allergy to the specific food trigger is identified. Consultation to dietitian is recommended.

Complementary Therapies

  • The full set NICE guidelines has a section on complementary therapies including herbal medicine, homeotherapy, massage, hypnotherapy, aromatherapy and food supplements and concluded that no or limited evidences are available.
  • Traditional Chinese Medicine medicines (TCM) are commonly used locally. In the Cochrane Systemiatic review of four small RCTs, oral Chinese herbal mixtures containing Zemaphyte may be effective in the treatment of atopic eczema.26 A latest review on clinical and laboratory research evidences for various TCM in eczema showed that some small studies demonstrated efficacy but results are inconsistent.27 Adverse effects including liver and cardiac toxicity can be potentially serious. Future larger scale studies are required to delineate the role of TCM in treatment of eczema. Parents should also be alerted that topical steroids have been found in herbal creams as reported locally and overseas.28,29 Advise parents to attend registered TCM practitioners should they choose it as complementary therapy.
  • The effectiveness of probiotic therapy is still doubtful and further studies are required to establish its role and efficacy.5

Education and Psychosocial Support

  • Parent/patient education should aim at empowerment in self-management, improving coping skills and facilitating doctor-patient partnership.
  • The guidelines emphasize the importance of provision of information, involvement of parents and child in management including discussion, demonstration and written instructions for use of emollients and topical treatment.
  • Steroid-phobia is common and may cause treatment failure.30,31 Educate parents on adherence to treatment and advise on early treatment to control inflammation during exacerbation to break the itch-scratch cycle.
  • Patients having more severe itchiness and behavioural disturbances, individual or group psychological interventions are useful adjunctive treatment.5,6

Conclusion

A holistic approach is the key to success in management of atopic eczema in children.


References

1. Wong GW, Leung TF, Ma Y, Liu EK, Yung E, Lai CK. Symptoms of asthma and atopic disorders in preschool children: prevalence and risk factors. Clin Exp Allergy 2007;37:174-9.

2. Lee SL, Wong W, Lau YL. IIncreasing prevalence of allergic rhinitis but not asthma among children in Hong Kong from 1995 to 2001 (Phase 3 International Study of Asthma and Allergies in Childhood). Pediatr Allergy Immunol 2004b;15:72-8.

3. Wong GW, Leung TF, Ko FW, et al. Declining asthma prevalence in Hong Kong Chinese schoolchildren. Clin Exp Allergy 2004;34:1550-5.

4. National Institute for Health and Clinical Excellence. Atopic eczema in children. Management of atopic eczema in children from birth up to age of 12 years. NICE clinical guideline 57, December 2007. Available at http://guidance.nice.org.uk/CG57.

5. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006;61:969-87.

6. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol 2004;50:391-404.

7. Saeki H, Furue M, Furukawa F, et al.; Committee for Guidelines for the Management of Atopic Dermatitis of Japanese Dermatological Assoication. Guidelines for management of atopic dermatitis. J Dermatol 2009;36:563-77.

8. Hon KL, Leung AK. Chapter on Use of Moisturizers in Patients with Atopic Dermatitis. Treatment of Dry Skin Syndrome. Lodén M, Maibach HI (eds.), Springer-Verlag Berlin Heidelberg, 2012.

9. Hon KL, Leung AK. Use of Ceramides and Related Products for Childhood-Onset Eczema. Recent Pat Inflamm Allergy Drug Discov 2012 Oct 17. [Epub ahead of print].

10. Long CC, Finlay AY. The finger-tip unit--a new practical measure. Clin Exp Dermatol 1991;16(6):444-7.

11. NHS Prodigy Guidance on Atopic Eczema. Available at: www.cks.library.nhs.uk/eczema_atopic.

12. Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007;156:203-21.

13. Topical steroid. In, Vol. 2011: Wikimedia Foundation Inc, 2011.

14. Oranje AP, Devillers AC, Kunz B, et al. Treatment of patients with atopic dermatitis using wet-wrap dressings with diluted steroids and/or emollients. An expert panel's opinion and review of the literature. J Eur Acad Dermatol Venereol 2006;20:1277-86.

15. National Institute for Clinical Excellence. Tacrolimus and pimecrolimus for atopic eczema. Technology Apprasial Guidance 82, August 2004. Available: http://www.nice.org.uk/nicemedia/pdf/TA082publicinfo.pdf

16. Berger TG, Duvic M, Van Voorhees AS, et al. American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006;54:818-23.

17. US Food and Drug Adminstration, US Department of Health and Human Services, 19 January 2006. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108580.htm.

18. Schmitt J, Schäkel K, Schmitt N, Meurer M. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol 2007;87:100-11.

19. Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000;142:52-8.

20. Grundmann SA, Beissert S. Modern aspects of phototherapy for atopic dermatitis. J Allergy (Cairo) 2012;121797. Epub 2011 Dec 15.

21. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 2009;123:e808-14.

22. Werfel T, Ballmer-Weber B, Eigenmann PA, et al. Eczematous reactions to food in atopic eczema: position paper of EAACI and GA2LEN. Allergy 2007;62:723-8.

23. National Institute for Health and Clinical Excellence. Food allergy in Children and young people. Diagnosis and assessment of aloof allergy in children and young people in primary care and community settings. NICE clinical guideline CG116, Februrary 2011. Available at: http://guidance.nice.org.uk/CG116.

24. Niggemann B, Beyer K. Diagnostic pitfalls in food allergy in children. Allergy 2005;60:104-7.

25. ESPGHAN Committee on Nutrition; Agostoni C, Axelsson I, Goulet O, et al. Soy protein infant formulae and follow-on formulae: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2006;42:352-61.

26. Zhang W, Leonard T, Bath-Hextall FJ, Chambers C, Lee C, Humphreys R, Williams HC. Chinese herbal medicine for atopic eczema. Cochrane Skin Group Cochrane Database of Systematic Reviews. Published in Issue 8, 2010.

27. Hon KL, Chan BCL, Leung PC. Chinese herbal medicine research in eczema treatment. Chin Med 2011;6:17.

28. Ramsay HM, Goddard W, Gill S, Moss C. Herbal creams used for atopic eczema in Birmingham, UK illegally contain potent corticosteroids. Arch Dis Child 2003;88:1056-7.

29. Hon KL, Leung TF, Yau HC, Chan T. Paradoxical use of oral and topical steroids in steroid-phobic patients resorting to traditional Chinese medicines. World J Pediatr 2012;8:263-7.

30. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931-6.

31. Hon KL, Kam WY, Leung TF, et al. Steroid fears in children with eczema. Acta Paediatr 2006;95:1451-5.

 
 

©2018 Hong Kong Journal of Paediatrics. All rights reserved. Developed and maintained by Medcom Ltd.